Search Results

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

• Authors : Kınıkoğlu, Oğuzcan¹ (AUTHOR) ; Öven, Bala Başak² (AUTHOR) ; Çelik, Serkan² (AUTHOR)

• Source: Journal of Clinical Medicine. Aug2024, Vol. 13 Issue 16, p4585. 14p.

Record details

Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F]AlF2+ method

• Authors : Marco Nicola Iannone; Silvia Valtorta; Stefano Stucchi

Subjects: PSMA-617; NODA; RESCA

• Source: EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-30 (2024)

Record details

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (CaboLu)

• Authors : Exelixis

• Source: A Phase Ib Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

Record details

Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions

• Authors : Martin Schäfer; Ulrike Bauder-Wüst; Mareike Roscher

Subjects: Chemistry; QD1-999

• Source: ACS Omega, Vol 10, Iss 7, Pp 7077-7090 (2025)

Record details

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225

• Authors : Meyer, Catherine; Prasad, Vikas; Stuparu, Andreea

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; Oncology and Carcinogenesis

• Source: EJNMMI Research. 12(1)

Record details

Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p)

• Authors : National Health and Medical Research Council, Clinical Trials Centre; Prostate Cancer Research Alliance; Endocyte

• Source: ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)

Record details

Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F]AlF2+ method

• Authors : Iannone, M; Valtorta, S; Stucchi, S

Subjects: Automation; Fluorine-18; Glioma

Record details

Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit

• Authors : J. B. Schnog; A. J. Duits; M. J. Samson

Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282

• Source: BJC Reports, Vol 2, Iss 1, Pp 1-4 (2024)

Record details

Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?

• Authors : Taş, Harun¹ (AUTHOR) ; Bakos, Gábor¹ (AUTHOR) ; Bauder-Wüst, Ulrike¹ (AUTHOR)

• Source: Pharmaceuticals (14248247). Apr2024, Vol. 17 Issue 4, p513. 14p.

Record details

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225

• Authors : Catherine Meyer; Vikas Prasad; Andreea Stuparu

Subjects: PSMA-TO-1; PSMA-617; Prostate cancer

• Source: EJNMMI Research, Vol 12, Iss 1, Pp 1-11 (2022)

Record details